sarecycline rosacea
Selected indexed studies
- Guidelines of care for the management of acne vulgaris. (J Am Acad Dermatol, 2024) [PMID:38300170]
- Sarecycline: First Global Approval. (Drugs, 2019) [PMID:30659422]
- Oral Sarecycline for Treatment of Papulopustular Rosacea: Results of a Pilot Study of Effectiveness and Safety. (J Drugs Dermatol, 2021) [PMID:33852248]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Sarecycline: First Global Approval. (2019) pubmed
- Guidelines of care for the management of acne vulgaris. (2024) pubmed
- Sarecycline: A Narrow-Spectrum Antibiotic. (2022) pubmed
- Emerging Medical Therapies in Rosacea: A Narrative Review. (2023) pubmed
- Oral Sarecycline for Treatment of Papulopustular Rosacea: Results of a Pilot Study of Effectiveness and Safety. (2021) pubmed
- Sarecycline as a Potential Treatment for Steroid-Induced Rosacea/Perioral Dermatitis: A Case Report. (2024) pubmed
- Acne and rosacea therapies see the light. (2023) pubmed
- Sarecycline Demonstrates Clinical Effectiveness against Staphylococcal Infections and Inflammatory Dermatoses: Evidence for Improving Antibiotic Stewardship in Dermatology. (2022) pubmed
- Tetracyclines Revisited: Tetracyclines in the Field of Dermatology. (2024) pubmed
- Oral Tetracycline-Class Drugs in Dermatology: Impact of Food Intake on Absorption and Efficacy. (2023) pubmed